Related references
Note: Only part of the references are listed.Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Strategies and industrial perspectives to improve oral absorption of biological macromolecules
Chang Liu et al.
EXPERT OPINION ON DRUG DELIVERY (2018)
Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus
Bruno Verges et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
alpha-Helix or beta-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4
Alberto Oddo et al.
BIOCHEMISTRY (2018)
Bone markers and cardiovascular risk in type 2 diabetes patients
Sabine R. Zwakenberg et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease Results of the LEADER Trial
Subodh Verma et al.
CIRCULATION (2018)
Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons
Jessica M. Adams et al.
DIABETES (2018)
Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial
Michael A. Nauck et al.
DIABETES & VASCULAR DISEASE RESEARCH (2018)
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin
Ildiko Lingvay et al.
DIABETES CARE (2018)
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
Bernard Zinman et al.
DIABETES CARE (2018)
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
Bo Ahren et al.
DIABETES OBESITY & METABOLISM (2018)
Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
Lene Jensen et al.
DIABETES OBESITY & METABOLISM (2018)
Incretin hormones: Their role in health and disease
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2018)
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease
Seung Pil Yun et al.
NATURE MEDICINE (2018)
Fire prevention in the Parkinson's disease brain
Lena Brundin et al.
NATURE MEDICINE (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Daniel J. Drucker
DIABETES (2018)
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
Ketan Dhatariya et al.
DIABETES CARE (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Structure of the glucagon receptor in complex with a glucagon analogue
Haonan Zhang et al.
NATURE (2018)
Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment
Casper Bo Gravesen Salinas et al.
SCIENTIFIC REPORTS (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
Stephen T. Buckley et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
Gunaj Rakipovski et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial
Laszlo Hegedus et al.
DIABETES CARE (2018)
GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca2+ channels
Reshma Ramracheya et al.
PHYSIOLOGICAL REPORTS (2018)
Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity
Julie B. Hjerpsted et al.
DIABETES OBESITY & METABOLISM (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization
Casper Bo Jensen et al.
ENDOCRINOLOGY (2018)
GLP-1 Receptor Expression Within the Human Heart
Laurie L. Baggio et al.
ENDOCRINOLOGY (2018)
The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice
Melissa A. Burmeister et al.
DIABETES (2017)
Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
Lene Jensen et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial
Melanie Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion
Caroline K. Kramer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques
Sarah R. Langley et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight
Ronald P. Gaykema et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
Structure of the full-length glucagon class B G-protein-coupled receptor
Haonan Zhang et al.
NATURE (2017)
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Yan Zhang et al.
NATURE (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m2: A Post-hoc Analysis
Carel le Roux et al.
OBESITY FACTS (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Bo Ahren et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Semaglutide, lipid-lowering drugs, and NAFLD
Niki Katsiki et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Christopher Sorli et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
The dynamic plasticity of insulin production in β-cells
Brandon B. Boland et al.
MOLECULAR METABOLISM (2017)
The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
Laurie L. Baggio et al.
MOLECULAR METABOLISM (2017)
Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment
Michael Gejl et al.
SCIENTIFIC REPORTS (2017)
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
Thomas C. Marbury et al.
CLINICAL PHARMACOKINETICS (2017)
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Blundell et al.
DIABETES OBESITY & METABOLISM (2017)
The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Anne Orgaard et al.
DIABETOLOGIA (2017)
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
Christoph Kapitza et al.
DIABETOLOGIA (2017)
Liraglutide for weight management: a critical review of the evidence
A. Mehta et al.
OBESITY SCIENCE & PRACTICE (2017)
Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver-α-Cell Axis
Jens J. Holst et al.
DIABETES (2017)
Intestinal GLP-1 and satiation: from man to rodents and back
R. E. Steinert et al.
INTERNATIONAL JOURNAL OF OBESITY (2016)
Human Validation of Genes Associated With a Murine Atherosclerotic Phenotype
Gerard Pasterkamp et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy
Henrik H. Hansen et al.
BRAIN RESEARCH (2016)
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
Manfredi Rizzo et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Never Waste a Good Crisis: Confronting Reproducibility in Translational Research
Daniel J. Drucker
CELL METABOLISM (2016)
Parabrachial CGRP Neurons Control Meal Termination
Carlos A. Campos et al.
CELL METABOLISM (2016)
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease New Insights From Epidemiology, Genetics, and Biology
Borge G. Nordestgaard
CIRCULATION RESEARCH (2016)
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
Michael Nauck et al.
DIABETES CARE (2016)
Exposure-response analyses of liraglutide 3.0 mg for weight management
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2016)
Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)
Eun Ji Park et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation
Claus H. Bang-Berthelsen et al.
INFLAMMATORY BOWEL DISEASES (2016)
Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R)
Dehua Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus
Joep van der Leeuw et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
Nicolai J. Wewer Albrechtsen et al.
JOURNAL OF DIABETES RESEARCH (2016)
Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements
David G. Levitt et al.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2016)
GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
Jacqueline A. Koehler et al.
CELL METABOLISM (2015)
GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R
Bernardo Yusta et al.
DIABETES (2015)
Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
Daniel J. Drucker
DIABETES (2015)
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
Juris J. Meier et al.
DIABETES CARE (2015)
Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain
Kristy M. Heppner et al.
ENDOCRINOLOGY (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial
Caroline K. Kramer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Islet α cells and glucagon-critical regulators of energy homeostasis
Jonathan E. Campbell et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice
Gunnar Sorensen et al.
PHYSIOLOGY & BEHAVIOR (2015)
A Method for Combining RNAscope In Situ Hybridization with Immunohistochemistry in Thick Free-Floating Brain Sections and Primary Neuronal Cultures
Tessa M. Grabinski et al.
PLOS ONE (2015)
Structural similarities and differences between the human and the mouse pancreas
Jurij Dolensek et al.
ISLETS (2015)
Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics
Kine Marita Knudsen Sand et al.
FRONTIERS IN IMMUNOLOGY (2015)
Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
Simon C. Cork et al.
MOLECULAR METABOLISM (2015)
Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas
Beatrice Waser et al.
MODERN PATHOLOGY (2015)
Progress in detecting cell-surface protein receptors: the erythropoietin receptor example
Steve Elliott et al.
ANNALS OF HEMATOLOGY (2014)
Structure of Class B GPCRs: new horizons for drug discovery
Andrea Bortolato et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Hypothalamic Tanycytes Are an ERK-Gated Conduit for Leptin into the Brain
Eglantine Balland et al.
CELL METABOLISM (2014)
GLP-1 Provoked Severe Hypoglycemia in an Individual With Type 2 Diabetes and a Benign Insulinoma
Ronald J. Ruby et al.
DIABETES CARE (2014)
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
Carol Wysham et al.
DIABETES CARE (2014)
Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
Andrew E. Hogan et al.
DIABETOLOGIA (2014)
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Charles Pyke et al.
ENDOCRINOLOGY (2014)
A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells
David J. Brayden et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2014)
Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
M. E. J. Lean et al.
INTERNATIONAL JOURNAL OF OBESITY (2014)
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
J. van Can et al.
INTERNATIONAL JOURNAL OF OBESITY (2014)
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Anna Secher et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
Laurie L. Baggio et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect
Stephanie Sisley et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
L. van Bloemendaal et al.
JOURNAL OF ENDOCRINOLOGY (2014)
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Kathleen M. Dungan et al.
LANCET (2014)
Drugs derived from phage display From candidate identification to clinical practice
Andrew E. Nixon et al.
MABS (2014)
Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior
Rozita H. Anderberg et al.
PHYSIOLOGY & BEHAVIOR (2014)
A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
Yuko Tashiro et al.
PEPTIDES (2014)
Effects of GLP-1 in the Kidney
Jeppe Skov
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2014)
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice
Lital Rachmany et al.
AGE (2013)
The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
Astrid Plamboeck et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2013)
Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH2] in postmenopausal women with osteoporosis
K. Henriksen et al.
BONE (2013)
Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
Weike Bao et al.
CARDIOVASCULAR DIABETOLOGY (2013)
The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model
Tracey Gaspari et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes The T-emerge 2 trial
Julio Rosenstock et al.
DIABETES CARE (2013)
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2013)
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice
Naim Panjwani et al.
ENDOCRINOLOGY (2013)
Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice
Niels-Erik Viby et al.
ENDOCRINOLOGY (2013)
The Glucagon-Like Peptide-1 Receptor-or Not?
Charles Pyke et al.
ENDOCRINOLOGY (2013)
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
T. A. Wadden et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Tanycyte-like cells form a blood-cerebrospinal fluid barrier in the circumventricular organs of the mouse brain
Fanny Langlet et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2013)
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse et al.
LANCET (2013)
Common variants associated with plasma triglycerides and risk for coronary artery disease
Ron Do et al.
NATURE GENETICS (2013)
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
Minsuk Kim et al.
NATURE MEDICINE (2013)
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia
Martin Lorenz et al.
REGULATORY PEPTIDES (2013)
Impact of Diabetes on Cardiovascular Disease: An Update
Alessandra Saldanha de Mattos Matheus et al.
INTERNATIONAL JOURNAL OF HYPERTENSION (2013)
Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
Changting Xiao et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Liraglutide: short-lived effect on gastric emptyingulong lasting effects on body weight
J. Jelsing et al.
DIABETES OBESITY & METABOLISM (2012)
Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
T. Forst et al.
DIABETIC MEDICINE (2012)
18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma
Dale O. Kiesewetter et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Impact of albumin on drug delivery - New applications on the horizon
Bakheet Elsadek et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
Nadeem Sarwar et al.
LANCET (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Exendin-4 decreases amphetamine-induced locomotor activity
Kevin Erreger et al.
PHYSIOLOGY & BEHAVIOR (2012)
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Ib Jonassen et al.
PHARMACEUTICAL RESEARCH (2012)
Functional importance of GLP-1 receptor species and expression levels in cell lines
Lotte Bjerre Knudsen et al.
REGULATORY PEPTIDES (2012)
Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor
Jan Terje Andersen et al.
NATURE COMMUNICATIONS (2012)
The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
Christoph Kapitza et al.
ADVANCES IN THERAPY (2011)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes
J. Z. Dong et al.
DIABETES OBESITY & METABOLISM (2011)
Encapsulation of Exenatide in Poly-(D,L-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
Mary Beth DeYoung et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
Laszlo Hegedus et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials
M. A. Karsdal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug
Lisbeth V. Jacobsen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
Anne Flint et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Unique Arrangement of α- and β-Cells in Human Islets of Langerhans
Domenico Bosco et al.
DIABETES (2010)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase
Monika Malm-Erjefalt et al.
DRUG METABOLISM AND DISPOSITION (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy
Morten A. Karsdal et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes
Erin L. St Onge et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Ulrich Werner et al.
REGULATORY PEPTIDES (2010)
Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model
Jens Kristensen et al.
BMC CARDIOVASCULAR DISORDERS (2009)
Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota
Patrice D. Cani et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
Age-Dependent Decline in beta-Cell Proliferation Restricts the Capacity of beta-Cell Regeneration in Mice
Shuen-Ing Tschen et al.
DIABETES (2009)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
M. A. Bush et al.
DIABETES OBESITY & METABOLISM (2009)
Lessons from the Crystallographic Analysis of Small Molecule Binding to Human Serum Albumin
Stephen Curry
DRUG METABOLISM AND PHARMACOKINETICS (2009)
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
Hongbin Liu et al.
JOURNAL OF ENDOCRINOLOGY (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice
Gitte Jositsch et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2009)
Should we be cautious on the use of commercially available antibodies to dopamine receptors?
Serena Bodei et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2009)
Lack of specificity of antibodies directed against human beta-adrenergic receptors
Nazha Hamdani et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2009)
Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors
Wisuit Pradidarcheep et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2009)
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Yazhou Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Molecular evolution of mammalian incretin hormone genes
David M. Irwin
REGULATORY PEPTIDES (2009)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
J. -P. Courreges et al.
DIABETIC MEDICINE (2008)
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
T. Vilsboll et al.
DIABETIC MEDICINE (2008)
Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain
Steffen Runge et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Felix Kratz
JOURNAL OF CONTROLLED RELEASE (2008)
Engineering of a femtomolar affinity binding protein to human serum albumin
Andreas Jonsson et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2008)
Partial pancreatectomy in adult humans does not provoke beta-cell regeneration
Bjoern A. Menge et al.
DIABETES (2008)
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: Importance of fatty acid length, polarity, and bulkiness
Kjeld Madsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Sandeep Bansal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
GLP-1 receptor expression in human tumors and human normal tissues:: Potential for in vivo targeting
Meike Koerner et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice
Desu Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Small-molecule agonists for the glucagon-like peptide 1 receptor
Lotte Bjerre Knudsen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Biomarkers of atherosclerotic plaque instability and rupture
Wolfgang Koenig et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not
Kirsten Raun et al.
DIABETES (2007)
Combining laser capture microdissection with quantitative real-time PCR: Effects of tissue manipulation on RNA quality and gene expression
Ilan A. Kerman et al.
JOURNAL OF NEUROSCIENCE METHODS (2006)
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
JJ Meier et al.
DIABETOLOGIA (2006)
Insulin detemir: from concept to clinical experience
P Home et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
OG Kolterman et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2005)
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes
KB Degn et al.
DIABETES (2004)
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis
LL Baggio et al.
DIABETES (2004)
The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin
S Havelund et al.
PHARMACEUTICAL RESEARCH (2004)
Inflammation as a cardiovascular risk factor
JT Willerson et al.
CIRCULATION (2004)
GLP-1 derivative liraglutide in rats with β-cell deficiencies:: influence of metabolic state on β-cell mass dynamics
J Sturis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
MJ During et al.
NATURE MEDICINE (2003)
Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity
S Runge et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan
C Chaudhury et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
L Farilla et al.
ENDOCRINOLOGY (2002)
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice
B Rolin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2002)
Interleukin-1 receptor antagonist: A sensitive marker of instability in patients with coronary artery disease
G Patti et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2002)
Albumin binding as a general strategy for improving the pharmacokinetics of proteins
MS Dennis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsboll et al.
DIABETOLOGIA (2002)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
A novel neutrotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells
T Perry et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
J Larsen et al.
DIABETES CARE (2001)
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
CMB Edwards et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2001)
Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin
AA Bhattacharya et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
LB Knudsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas
DA Stoffers et al.
DIABETES (2000)
Share Paper
